LON:SN - Smith & Nephew Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 1,470 -6.50 (-0.44 %) (As of 04/24/2019 02:00 PM ET)Previous CloseGBX 1,476.50Today's RangeGBX 1,466 - GBX 1,47852-Week RangeGBX 1,242.50 - GBX 1,548.50Volume1.77 million shsAverage Volume3.25 million shsMarket Capitalization£12.84 billionP/E Ratio19.42Dividend Yield1.82%BetaN/A ProfileDiscussionAnalyst RatingsChartDividendInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. Additionally, it offers meniscal repair system. It primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom. Receive SN News and Ratings via Email Sign-up to receive the latest news and ratings for SN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Medical Appliances & Equipment Sub-IndustryN/A SectorMedical Current SymbolLON:SN Previous Symbol CUSIPN/A CIKN/A Webwww.smith-nephew.com Phone+44-20-74017646Debt Debt-to-Equity Ratio30.12 Current Ratio2.10 Quick Ratio1.08Price-To-Earnings Trailing P/E Ratio19.42 Forward P/E Ratio14.55 P/E GrowthN/A Sales & Book Value Annual Sales£4.90 billion Price / Sales2.62 Cash FlowGBX 42.54 per share Price / Cash Flow34.56 Book ValueGBX 557.60 per share Price / Book2.64Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees16,377 Outstanding Shares873,356,992Market Cap£12.84 billion Next Earnings DateN/A OptionableOptionable Smith & Nephew (LON:SN) Frequently Asked Questions What is Smith & Nephew's stock symbol? Smith & Nephew trades on the London Stock Exchange (LON) under the ticker symbol "SN." How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew? Smith & Nephew announced a dividend on Thursday, February 7th. Stockholders of record on Thursday, April 4th will be given a dividend of GBX 0.22 per share on Wednesday, May 8th. This represents a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, April 4th. This is an increase from Smith & Nephew's previous dividend of $0.14. The official announcement can be viewed at this link. View Smith & Nephew's Dividend History. What price target have analysts set for SN? 11 brokerages have issued 1-year price objectives for Smith & Nephew's stock. Their predictions range from GBX 1,350 to GBX 1,692. On average, they anticipate Smith & Nephew's share price to reach GBX 1,479.36 in the next twelve months. This suggests a possible upside of 0.6% from the stock's current price. View Analyst Price Targets for Smith & Nephew. What is the consensus analysts' recommendation for Smith & Nephew? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Smith & Nephew. Has Smith & Nephew been receiving favorable news coverage? Media headlines about SN stock have trended very positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Smith & Nephew earned a daily sentiment score of 3.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. Who are some of Smith & Nephew's key competitors? Some companies that are related to Smith & Nephew include Consort Medical (CSRT), Corindus Vascular Robotics (CVRS), Ekf Diagnostics (EKF), Theralase Technologies (TLT), Immunodiagnostic Systems (IDH), LiDCO Group (LID), Intelligent Ultrasound Group (MED), Deltex Medical Group (DEMG), Zecotek Photonics (ZMS), InspireMD (NSPR), Bioquell (BQE), Lucid (LCDX) and Verisante Technology (VRS). What other stocks do shareholders of Smith & Nephew own? Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Imperial Brands (IMB), Smith & Nephew (SNN), Alexion Pharmaceuticals (ALXN), Barclays (BARC), Aviva (AV), BAE Systems (BA), GlaxoSmithKline (GSK), Standard Chartered (STAN), Anglo American (AAL) and AstraZeneca (AZN). Who are Smith & Nephew's key executives? Smith & Nephew's management team includes the folowing people: Mr. Namal Nawana, CEO & Exec. Director (Age 48)Mr. Graham Timothy Baker, CFO & Exec. Director (Age 51)Mr. Mark Gladwell, Pres of Global Operations (Age 44)Ms. Catheryn O'Rourke, Chief Legal & Compliance Officer (Age 46)Mr. Joe Metzger, Sr. VP of Marketing Services & Communications How do I buy shares of Smith & Nephew? Shares of SN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Smith & Nephew's stock price today? One share of SN stock can currently be purchased for approximately GBX 1,470. How big of a company is Smith & Nephew? Smith & Nephew has a market capitalization of £12.84 billion and generates £4.90 billion in revenue each year. Smith & Nephew employs 16,377 workers across the globe. What is Smith & Nephew's official website? The official website for Smith & Nephew is http://www.smith-nephew.com/. How can I contact Smith & Nephew? Smith & Nephew's mailing address is 15 Adam Street, LONDON, WC2N 6LA, United Kingdom. The company can be reached via phone at +44-20-74017646. MarketBeat Community Rating for Smith & Nephew (LON SN)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 474 (Vote Outperform)Underperform Votes: 584 (Vote Underperform)Total Votes: 1,058MarketBeat's community ratings are surveys of what our community members think about Smith & Nephew and other stocks. Vote "Outperform" if you believe SN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: Certificate of Deposit (CD) For Risk Adverse Investors?